Welcome to Psychiatryai.com: Latest Evidence - RAISR4D

Estimated reading time for CME/CPD: 2 mins

Identification of Gene Signatures and Molecular Mechanisms Underlying the Comorbidity of Alzheimer’s Disease and Crohn’s Disease Using Machine Learning

AI Summary
  • Machine learning integration identified CXCL1 and IGFBP5 as core genes underlying Alzheimer's and Crohn's disease comorbidity.
  • CXCL1 and IGFBP5 mediate inflammation, immune regulation, cell migration, and tissue remodelling, potentially linking gut-brain axis and IgSF CAM signalling.
  • Virtual knockout, single-cell validation, and molecular docking nominate Dasatinib, Mifepristone, and Retinoic acid as candidate targeted therapies.
Summarise with AI (MRCPsych/FRANZCP)

Psychiatry Investig. 2026 Sep 22. doi: 10.30773/pi.2026.0214. Online ahead of print.

ABSTRACT

OBJECTIVE: Alzheimer’s disease (AD) and Crohn’s disease (CD) both involve inflammation and immune dysregulation, yet the potential molecular mechanisms underlying their comorbidity remain unclear.

METHODS: We integrated transcriptomic data from AD and CD patients and applied differential expression analysis, weighted gene coexpression network analysis, protein-protein interaction networks, and multiple machine learning approaches to identify key comorbidity genes. Functional enrichment, single-cell sequencing validation, and virtual knockout analyses were used to explore their biological roles. Molecular docking was performed to evaluate the binding affinity of candidate small-molecule drugs to the identified core genes.

RESULTS: CXCL1 and IGFBP5 were identified as core comorbidity genes. CXCL1 was associated with inflammatory signaling, including cytokine receptor binding, neutrophil migration, and NOD-like receptor signaling. IGFBP5 was linked to growth factor binding, smooth muscle cell proliferation, and extracellular matrix-receptor interactions. Single-cell and virtual knockout analyses indicated that these genes play pivotal roles in inflammation, immune regulation, cell migration, and tissue remodeling, potentially bridging central and peripheral inflammation via the gut-brain axis and IgSF CAM signaling. Candidate drug prediction and molecular docking suggested that small molecules such as Dasatinib, Mifepristone, and Retinoic acid may modulate these pathways.

CONCLUSION: This study reveals the critical roles of CXCL1 and IGFBP5 in AD-CD comorbidity, providing a theoretical basis for exploring gut-brain axis mechanisms and potential targeted interventions.

PMID:42765175 | DOI:10.30773/pi.2026.0214

Document this CPD

Share Evidence Blueprint

QR Code

Save to Google Notes

Search Google Scholar

Save as PDF

My Revision List

close chatgpt icon
ChatGPT

Enter your request.

← →
RAISR4D CME/CPD Evidence Nodes
Swipe to navigate RAISR4D CME/CPD evidence nodes.
CME/CPD